von Robert | Aug. 1, 2025 | Uncategorized
Timm-H. Jessen Appointed Managing Director Cutanos GmbH announces a leadership transition as co-founder and CEO Dr. Robert Wawrzinek takes a break steps down from his role for personal reasons. Dr. Wawrzinek will continue to support the company as a board member and...
von Robert | Juli 1, 2025 | Uncategorized
Langerhans Cell-targeted mRNA Delivery: A Strategy for Dose-Sparing and Enhanced Anti-Tumor Immunity Despite the success of mRNA therapeutics, challenges remain in optimizing immune responses and minimizing side effects. Cell-specific antigen delivery may help reduce...
von Robert | Juni 11, 2025 | Uncategorized
Langerhans Cell-targeted Protein Delivery Enhances Antigen-Specific Cellular Immune Response Targeted antigen delivery to immune cells, particularly dendritic cells, has emerged as a promising strategy to enhance therapeutic efficacy of vaccines, while minimizing...
von Robert | Juli 3, 2024 | Uncategorized
Cutanos Wins BARDA VITAL Prize Challenge for Innovative Vaccine Technology! Vienna, Austria (July 1, 2024) – Cutanos GmbH, a biotechnology company based in Vienna, Austria, was awarded first place in the BARDA VITAL Prize (BVP) Challenge, endowed with USD 20,000 by...
von Robert | Apr. 5, 2023 | Uncategorized
Welcome Ramona Rîca and Litty Johnson, the latest additions to Cutanos‘ science Team! With pleasure we welcome Ramona and Litty and are excited to add even more expertise in immunology and material science to our projects!...
